Alpha Cognition Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$1.24next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results & Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
ZUNVEYL Net Product Revenue Quarterly3.5MTarget: Operating profitability in 2027
ZUNVEYL Bottles Dispensed Quarterly6.1K
Active Prescribing Healthcare Providers (HCPs) Quarterly1.1K
Nursing Homes Reached / Penetrated Quarterly2.5K
Watch Items
- RESOLVE Phase 4 Post-Marketing Study EnrollmentTrigger: Completion of enrollment of ~150 patientsAction: Monitor enrollment progress through expected completion in Q2 2027 to support outpatient tolerability data.
- CONVERGE Retrospective LTC Study Topline DataTrigger: Release of topline dataAction: Review results expected in Q3 2026 evaluating tolerability, dosing, and polypharmacy in 400 LTC patients.
- Ex-US Regulatory Approvals (Asia/China)Trigger: Regulatory approval decisionsAction: Track partner CMS's progress toward anticipated approvals in China and other Asian markets by late 2026.
Research as of 19 Jun 2026